Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)

NCT01108445 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT01108445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01108445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Lead sponsor
Duke University
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2010
Completion date
April 30, 2015
Enrollment
131 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-clear cell renal cell carcinoma